Exonhit receives financial support from OSEO
At the beginning of the project during the first semester of 2012, an amount of €1,126,000 was paid to Exonhit. The consortium aims at developing new therapies for
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
According to the agreement, the companies will investigate the next generation of the Biological Nano Particles, Chatham’s recombinant adeno-associated virus-based gene therapy technology, through US-based hemophilia B clinical